Cart
sales@molnova.com
Home - Products - Angiogenesis - EGFR - CO-1686 hydrobromide

CO-1686 hydrobromide

CAS No. 1446700-26-0

CO-1686 hydrobromide( Rociletinib hydrobromide | AVL-301 hydrobromide | CNX-419 hydrobromide )

Catalog No. M11900 CAS No. 1446700-26-0

A potent, highly selective, irreversible inhibitor of mutant EGFR with Ki of 21.5 nM for EGFR L858R/T790M.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
50MG 147 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote
Group Booking Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    CO-1686 hydrobromide
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent, highly selective, irreversible inhibitor of mutant EGFR with Ki of 21.5 nM for EGFR L858R/T790M.
  • Description
    A potent, highly selective, irreversible inhibitor of mutant EGFR with Ki of 21.5 nM for EGFR L858R/T790M; shows 22-fold selective over WT EGFR; EGFR del19, T790M, L858R/T790M and L858R mutant kinases demonstrates the highest degree of inhibition at 0.1 uM; orally bioavailable.Breast Cancer Phase 2 Clinical.
  • In Vitro
    Rociletinib (0.1 μM) inhibits EGFR potently and irreversibly, and inhibits more than 50% of 23 targets. Rociletinib potently and selectively inhibits growth of NSCLC cells expressing mutant EGFR and induces apoptosis. Rociletinib resistant NSCLC cell lines are sensitive to AKT inhibition.
  • In Vivo
    Rociletinib (100 mg/kg/day, p.o.) demonstrates anti-tumor activity in NSCLC EGFR mutant xenograft models. Rociletinib (50 mg/kg bid, p.o.) demonstrates anti-tumor activity in human EGFR-L858R and EGFR-L858R-T790M expressing transgenic mice.
  • Synonyms
    Rociletinib hydrobromide | AVL-301 hydrobromide | CNX-419 hydrobromide
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    EGFR
  • Research Area
    Cancer
  • Indication
    Breast Cancer

Chemical Information

  • CAS Number
    1446700-26-0
  • Formula Weight
    636.4634
  • Molecular Formula
    C27H29BrF3N7O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 59 mg/mL
  • SMILES
    CC(=O)N1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)NC4=CC(=CC=C4)NC(=O)C=C)C(F)(F)F)OC.Br
  • Chemical Name
    2-Propenamide, N-[3-[[2-[[4-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]phenyl]-, hydrobromide (1:1)

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Walter AO, et al. Cancer Discov. 2013 Dec;3(12):1404-15. 2. Tjin Tham Sjin R, et al. Mol Cancer Ther. 2014 Jun;13(6):1468-79. 3. Sequist LV, et al. N Engl J Med. 2015 Apr 30;372(18):1700-9.
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • Vandetanib

    Vandetanib is an orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability.

  • Allitinib

    Allitinib (AST-1306) has anti-cancer activity，and it is an irreversible EGFR and ErbB2 inhibitor with IC50s of 0.5 and 3 nM, respectively.

  • LDC4297

    LDC4297 is a potent and selective CDK7 inhibitor.

Sign In Join Free